113 related articles for article (PubMed ID: 11142690)
1. Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.
Smorenburg CH; Seynaeve C; Bontenbal M; Planting AS; Sindermann H; Verweij J
Anticancer Drugs; 2000 Nov; 11(10):825-8. PubMed ID: 11142690
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
Terwogt JM; Mandjes IA; Sindermann H; Beijnen JH; ten Bokkel Huinink WW
Br J Cancer; 1999 Mar; 79(7-8):1158-61. PubMed ID: 10098751
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.
Leonard R; Hardy J; van Tienhoven G; Houston S; Simmonds P; David M; Mansi J
J Clin Oncol; 2001 Nov; 19(21):4150-9. PubMed ID: 11689583
[TBL] [Abstract][Full Text] [Related]
4. Miltefosine: new preparation. Solution for cutaneous application.
Prescrire Int; 1998 Feb; 7(33):5-6. PubMed ID: 10183390
[TBL] [Abstract][Full Text] [Related]
5. Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.
Clive S; Gardiner J; Leonard RC
Cancer Chemother Pharmacol; 1999; 44 Suppl():S29-30. PubMed ID: 10602908
[TBL] [Abstract][Full Text] [Related]
6. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Unger C; Peukert M; Sindermann H; Hilgard P; Nagel G; Eibl H
Cancer Treat Rev; 1990 Sep; 17(2-3):243-6. PubMed ID: 2272039
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].
Mahieu-Renard L; Richard MA; Dales JP; Buscaylet S; Lagrassa S; Grob JJ
Ann Dermatol Venereol; 2005 Apr; 132(4):346-8. PubMed ID: 15886562
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.
Planting AS; Stoter G; Verweij J
Eur J Cancer; 1993; 29A(4):518-9. PubMed ID: 8435202
[TBL] [Abstract][Full Text] [Related]
9. [[Treatment with Miltex for metastatic skin lesions in breast cancer] ].
Moĭseenko VM; Orlova RV; Ermakova NA; Protsenko SA
Vopr Onkol; 2000; 46(5):600-3. PubMed ID: 11202195
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma.
Dumontet C; Thomas L; Bérard F; Gimonet JF; Coiffier B
Bull Cancer; 2006 Nov; 93(11):E115-8. PubMed ID: 17145574
[TBL] [Abstract][Full Text] [Related]
11. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Unger C; Sindermann H; Peukert M; Hilgard P; Engel J; Eibl H
Prog Exp Tumor Res; 1992; 34():153-9. PubMed ID: 1438798
[No Abstract] [Full Text] [Related]
12. [Multiple cutaneous plasmocytoma treated with topical applications of miltefosine].
Viseux V; Schoenlaub P; Danhier S; Vilque JP; Plantin P
Ann Dermatol Venereol; 2004 Feb; 131(2):204-5. PubMed ID: 15026752
[No Abstract] [Full Text] [Related]
13. Topical agents and dressings for fungating wounds.
Adderley U; Smith R
Cochrane Database Syst Rev; 2007 Apr; (2):CD003948. PubMed ID: 17443534
[TBL] [Abstract][Full Text] [Related]
14. A Phase 2 study of perifosine in advanced or metastatic breast cancer.
Leighl NB; Dent S; Clemons M; Vandenberg TA; Tozer R; Warr DG; Crump RM; Hedley D; Pond GR; Dancey JE; Moore MJ
Breast Cancer Res Treat; 2008 Mar; 108(1):87-92. PubMed ID: 17458693
[TBL] [Abstract][Full Text] [Related]
15. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study.
Dummer R; Krasovec M; Röger J; Sindermann H; Burg G
J Am Acad Dermatol; 1993 Dec; 29(6):963-70. PubMed ID: 8245262
[TBL] [Abstract][Full Text] [Related]
16. Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.
Unger C; Eibl H; Breiser A; von Heyden HW; Engel J; Hilgard P; Sindermann H; Peukert M; Nagel GA
Onkologie; 1988 Dec; 11(6):295-6. PubMed ID: 3071766
[No Abstract] [Full Text] [Related]
17. A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N') platinum in patients with refractory advanced breast cancer.
Theriault RL; Walters RS; Holmes FA; Esparza-Guerra L; Kowal C; Hortobagyi GN
Cancer Chemother Pharmacol; 1996; 38(3):289-91. PubMed ID: 8646805
[TBL] [Abstract][Full Text] [Related]
18. Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
Van Bocxlaer K; Yardley V; Murdan S; Croft SL
J Pharm Pharmacol; 2016 Jul; 68(7):862-72. PubMed ID: 27230300
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
Verweij J; Krzemieniecki K; Kok T; Poveda A; van Pottelsberghe C; van Glabbeke M; Mouridsen H
Eur J Cancer; 1993; 29A(2):208-9. PubMed ID: 8422284
[TBL] [Abstract][Full Text] [Related]
20. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]